AIM: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid(EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid(DHA) and dihomo-γ-linolenic acid(DGLA), relative to arachidonic acid(AA), in obese Japanese patients with dyslipidemia. METHODS: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obese patients with(n=94) and without (n=31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment(1.8g daily, n=45) or treatment without EPA(control, n=43). RESULTS: At baseline, the ratios of DHA/AA and DGLA/AA were significantly(P＜0.05) higher in obese patients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index(CAVI)(an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio(P＜0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. CONCLUSION: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obese patients with dyslipidemia.
AIM: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid(EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid(DHA) and dihomo-γ-linolenic acid(DGLA), relative to arachidonic acid(AA), in obese Japanese patients with dyslipidemia. METHODS: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obesepatients with(n=94) and without (n=31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment(1.8g daily, n=45) or treatment without EPA(control, n=43). RESULTS: At baseline, the ratios of DHA/AA and DGLA/AA were significantly(P＜0.05) higher in obesepatients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index(CAVI)(an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio(P＜0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. CONCLUSION: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obesepatients with dyslipidemia.
Authors: Zhongjie Fu; Wenjun Yan; Chuck T Chen; Anders K Nilsson; Edward Bull; William Allen; Jay Yang; Minji Ko; John Paul SanGiovanni; James D Akula; Saswata Talukdar; Ann Hellström; Lois E H Smith Journal: Nutrients Date: 2022-03-23 Impact factor: 6.706
Authors: Zhongjie Fu; Chuck T Chen; Gael Cagnone; Emilie Heckel; Ye Sun; Bertan Cakir; Yohei Tomita; Shuo Huang; Qian Li; William Britton; Steve S Cho; Timothy S Kern; Ann Hellström; Jean-Sébastien Joyal; Lois Eh Smith Journal: EMBO Mol Med Date: 2019-09-05 Impact factor: 14.260
Authors: Dominika Maciejewska; Małgorzata Michalczyk; Maja Czerwińska-Rogowska; Marcin Banaszczak; Karina Ryterska; Karolina Jakubczyk; Jakub Piotrwski; Joanna Hołowko; Arleta Drozd; Paweł Wysokińki; Krzysztof Ficek; Krzysztof Wilk; Anna Lubkowska; Paweł Cięszczyk; Jerzy Bertrand; Ewa Stachowska Journal: J Hum Kinet Date: 2017-12-28 Impact factor: 2.193
Authors: Zhongjie Fu; Raffael Liegl; Zhongxiao Wang; Yan Gong; Chi-Hsiu Liu; Ye Sun; Bertan Cakir; Samuel B Burnim; Steven S Meng; Chatarina Löfqvist; John Paul SanGiovanni; Ann Hellström; Lois E H Smith Journal: Invest Ophthalmol Vis Sci Date: 2017-08-01 Impact factor: 4.799
Authors: Brenda Kelly Souza Silveira; Thatianne Moreira Silva Oliveira; Patrícia Amaro Andrade; Helen Hermana Miranda Hermsdorff; Carla de Oliveira Barbosa Rosa; Sylvia do Carmo Castro Franceschini Journal: Cardiol Res Pract Date: 2018-03-14 Impact factor: 1.866